Fibrosing interstitial lung disease - An intravenous injection of a talc-containing drug Factor
Last reviewed for CCPS 16 December 2009.
Preliminary questions [40657]
40679 there is some evidence that intravenous injection of a talc-containing drug may be a factor in the development or worsening of the condition under consideration.
41042 the veteran has received an intravenous injection of a talc-containing drug intended for oral use at some time.41043 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and VEA service for fibrosing interstitial lung disease.
41044 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and VEA service for the clinical onset of fibrosing interstitial lung disease.
41046 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and operational service for the clinical onset of fibrosing interstitial lung disease.
or
41047 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and eligible service for the clinical onset of fibrosing interstitial lung disease.
or
7334
the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service. 7335
the condition under consideration permanently worsened.41045 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and VEA service for the clinical worsening of fibrosing interstitial lung disease.
41048 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and operational service for the clinical worsening of fibrosing interstitial lung disease.
or
41049 — the veteran has established the causal connection between the intravenous injection of a talc-containing drug intended for oral use and eligible service for the clinical worsening of fibrosing interstitial lung disease.
Clinical onset and operational service [41046]
41050
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years. 41052
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years within the ten years before the clinical onset of fibrosing interstitial lung disease. 41056
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years within the ten years before the clinical onset of fibrosing interstitial lung disease as a causal result of operational service. 41060
the intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years within the ten years before the clinical onset of fibrosing interstitial lung disease, as a causal result of operational service, was due to the veteran's serious default, wilful act or serious breach of discipline.Clinical onset and eligible service [41047]
41051
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years. 41053
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years within the ten years before the clinical onset of fibrosing interstitial lung disease. 41057
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years within the ten years before the clinical onset of fibrosing interstitial lung disease as a causal result of eligible service. 41061
the intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years within the ten years before the clinical onset of fibrosing interstitial lung disease, as a causal result of eligible service, was due to the veteran's serious default, wilful act or serious breach of discipline.Clinical worsening and operational service [41048]
41050
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years. 41054
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years after the clinical onset and within the ten years before the clinical worsening of fibrosing interstitial lung disease. 41058
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years after the clinical onset and within the ten years before the clinical worsening of fibrosing interstitial lung disease as a causal result of operational service. 41062
the intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least two years within the ten years before the clinical worsening of fibrosing interstitial lung disease, as a causal result of operational service, was due to the veteran's serious default, wilful act or serious breach of discipline.Clinical worsening and eligible service [41049]
41051
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years. 41055
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years after the clinical onset and within the ten years before the clinical worsening of fibrosing interstitial lung disease. 41059
the veteran received an intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years after the clinical onset and within the ten years before the clinical worsening of fibrosing interstitial lung disease as a causal result of eligible service. 41063
the intravenous injection of a talc-containing drug intended for oral use on more days than not for a period of at least three years within the ten years before the clinical worsening of fibrosing interstitial lung disease, as a causal result of eligible service, was due to the veteran's serious default, wilful act or serious breach of discipline.
